drugset / Trial / NCT05418972
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Phase 2
Active not recruiting
20 enrolled
Melanoma Institute Australia
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a pathological response after 2 doses of therapy.
Timeline
- Start
- 2023-08-14
- Primary completion
- 2025-12-11
- Completion
- 2035-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | Intravenous |